Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHRM 864 Module 4 > Hepatology > Flashcards

Hepatology Flashcards

(69 cards)

Start Studying
1
Q

Functionality of the liver

A

bile production (for digestion of foods + activation of pro drugs)
drug/food/toxin metabolism
protein synthesis (including albumin - for oncotic pressure in vascular system, and coagulation factors)
storage/adjustment of vitamins/gluconeogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Liver is heavily integrated into

A

GI system and is important for perfusion from the heart + vasculature system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Objective markers

A

aspatate transaminase
alanine transaminase
alkaline phosphatase
bilirubin
albumin
international normalized ratio
thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Aspartate transaminase (AST)

A

increases with acute liver injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Alanine transaminase (ALT)

A

increases with acute livery injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Alkaline phosphatase (alk phos)

A

increases with biliary tract injury from acute liver injury (i.e. gallstone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Bilirubin

A

increases with biliary tract injury from acute liver injury (i.e. gallstone) or chronic liver disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Albumin

A

decreases with chronic liver disease, malnutrition, CKD, or acute inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

International normalized ratio (INR)

A

increases with chronic liver disease, warfarin, or malnutrition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Thrombocytopenia

A

decreases with chronic liver disease, HIT, or malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Objective assessment summary

A

term LFTs are not true markers of liver fx: liver enzymes (AST, ALT, Alk phos) usually markers of acute liver injury
elevated bilirubin can be a sign of acute and/or chronic liver issues
chronic liver disease can decrease liver production of proteins resulting in: decreased albumin, increased INR, and/or increased bilirubin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the estimated incidence of drug-induced liver injury (DILI)?

A

14-19 cases per 100,000 persons
0.02%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the mechanisms/classifications of the different types of DILI?

A

direct
indirect
idiosyncratic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Direct

A

agents that are intrinsically toxic to the liver
ex. acetaminophen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Indirect

A

caused by the action of the drug (what it does)
ex. inducing metabolite abnormalities causing non-alcoholic fatty liver disease/steatotic liver disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Idiosyncratic

A

agents that have little or no intrinsic toxicity and that cause liver injury only in rare cases
ex. beta lactams, fluoroquinolones, macrolides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What medications are highest risk for causing DILI?

A

acetaminophen
anti-infectives: isoniazid, beta lactam antibiotics (penicillins, cephalosporins), fluoroquinolone antibiotics, macrolide antibiotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

If suspect DILI

A

hold offending agent
monitoring not recommended at baseline for most (except isoniazid as will be used for months)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Acetaminophen DILI

A

acute ingestion of high doses (>/= 8g acetaminophen) can result in toxic levels of N-acetyl-p-benzoquinone imine (NAPQI), which causes direct heptaotoxicity
s/sx: abdominal pain, jaundice, N/S/diarrhea
if not managed, can induce irreversible liver damage
assess severity through AST, ALT, and acetaminophen concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Goal of acetaminophen toxicity

A

reverse toxic metabolite through use of N-acetylcysteine (NAC) +/- activated charcoal (only if ingested <1hr prior, prevents absorption but not if taken more than 1 hr prior)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

N-acetylcysteine (NAC) MOA

A

binds NAPQI, decreaasing hepatotoxic effects
NAC mimics or restores glutathione –> helps conjugate NAPQI to a non-toxic metabolite (cysteine and mercapturic acid) –> can be excreted (no hepatotoxicity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

NAC indication/monitoring

A

based on concentration of acetaminophen (>/= 4 hours after ingestion) and timing since ingestion
NAC use determined by rumack-matthew nomogram - give NAC if level is above solid line
monitor: liver enzymes - AST/ALT (q12-24h) and s/sx
PO = IV in efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Acetaminophen DILI summary

A

assess timing of ingestion
using APAP concentration from lab and timing of ingestion, determine need for NAC using rumack-matthew nomogram
monitor liver enzymes + s/sx of acute liver injury
if intentional overdose, psychiatry evaluation appropriate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Cirrhosis

A

severe, chronic, irreversible fibrosis of the liver: associated with increased morbidity and mortality; annual mortality risk is 10% or more
complications are related and increase with severity (ex. hepatorenal syndrome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Causative factors of cirrhosis
chronic alcohol use (#1 in US) - stop drinking, can prevent progression, but can't reverse what's been done viral hepatitis metabolic liver disease (ex. hemochromatosis, nonalcoholic steatohepatitis) cholestatic liver disease (ex. primary biliary cirrhosis) drugs: chronic use of amiodarone, methotrexate
26
S/sx of cirrhosis
pruritus fatigue weight loss ascites juandice (accumulation of bilirubin) hepatomegaly or splenomegaly encephalopathy (confusion)
27
Cirrhosis complications
ascites, esophageal varices, hepatic encephalopathy, spontaneous bacterial peritonitis, thrombocytopenia, hyponatremia, hepatorenal syndrome
28
Diagnosing cirrhosis
s/sx markers of hepatic function (decreased albumin, increased INR) hepatic imaging liver biopsy (what is really used to diagnose)
29
Assessing severity of cirrhosis
child-pugh score model for end-stage liver disease (MELD): predicts 3 month-mortality risk and used in transplant prioritization (higher score, higher mortality risk)
30
Cirrhosis summary
irreversible disease with high morbidity and mortality multiple complications which are interconnected, but focus on the s/sx of the pt ideally, trying to prevent cirrhosis through alcohol cessation, treatment of viral hepatitis, monitoring/cessation of hepatotoxic meds
31
Ascites
fluid accumulation in the peritoneal space s/sx: abdominal distention, abdominal pain, SOB, nausea
32
Ascites pathophysiology
increased pressures with portal HTN drives fluid into peritoneal space compensatory mechanisms from portal HTN results in increased fluid retention hypoalbuminemia (decreased albumin production, less albumin in blood, decrease oncotic pressure, fluid goes outside into peritoneal space)
33
Ascites goals of care
minimize ascitic fluid accumulation and sx: improving QOL reduce need for paracentesis (invasice fluid removal) limit SEs from therapies prevent subsequent complications from uncontrolled ascites (SBP, hepatorenal syndrome)
34
Ascites management
non-pharmacologic: sodium restriction (<2g/day), assess for liver transplant first line: aldosterone antagonist (spironolactone) + loop diuretic (furosemide) second line: paracentesis; TIPS avoid NSAIDs in pts with cirrhosis
35
Diuretics for ascites
initiate at ratio of spiro 100:40 furo PO once daily combo is superior to monotherapy, but if using one, spiro is superior to furo in cirrhosis
36
SE/monitoring of diuretics
aldosterone antagonists: acute kidney injury, increased potassium, gynecomastia loop diuretics: acute kidney injury, decreased potassium monitoring: s/sx of ascites, SCr, K+
37
Paracentesis
second line for chronic management (can be used acutely if tense ascites) indicated in refractory/resistant ascites or in cases of AKI if >5L removed via paracentesis, albumin has been shown to decrease morbidity and mortality: administer 25% albumin IV and give 6-8g albumin per liter removed - this increases the serum albumin to have retention of more fluid in vasculature than peritoneal space
38
Albumin calculation
take the amount of liters removed and multiple by 6 or 8g
39
Ascites summary
assess s/sx for ascites, encourage non-pharm and diuretic therapy: monitor s/sx of ascites, renal fx, and potassium; paracentesis is 2nd line, unless treatment resistant (if AKI, not responsing/resistant)
40
Esophageal varices (EV)
portal HTN causes hepatic/splanchnic vasodilation resulting in decreased perfusion compensatory varices or small offshoots form: dilation of EV can occur and result in variceal bleeding, which can be severe
41
Risk factors for variceal bleeding
varices size (larger more likely to rupture) cirrhosis severity red color markings noted on endoscopy active alcohol use
42
Variceal bleeding prophylaxis
placebo RCTs of non-selective beta-blockers (NSBBs) or endoscopic variceal ligation (EVL) showed decreased variceal and GI bleeding, but no mortality benefit
43
Primary prohlyaxis for variceal bleeding
before a bleed ever occurs NSBB or EVL recommended monotherapy (not combo) NSBB: indicated in window of moderate disease: MOA - why non-selective beta blockers are important beta1 antagonism: decreased HR and CO beta2 antagonism: splanchnic vasoconstriction NSBBs target is to decrease CO
44
NSBBs SEs/monitoring
nadolol, propranolol, carvedilol SEs: drowsiness or insomnia, bradycardia, hypotension monitoring: HR: goal 55-60 bpm, BP: SBP > 90 mmHg, s/sx of VH
45
EVL
endoscopic procedure which bands off varices used as prophylaxis and treatment - primary prevention and management of acute variceal bleed
46
Variceal bleeding clinical presentation
esophageal varices - asymptomatic (visualized via endoscopy) variceal bleeding: hematemesis, melena, fatigue, lightheaded/dizziness, hypotension
47
Treatment of variceal bleeding
immediately upon presentation: blood transfusions (to maintain Hbg > 7), octreotide (vasoconstictor), antibiotic prohylaxis (to prevent SBP) PPIs not recommended for variceal bleeds
48
Surgical procedure for variceal bleeding
endoscopic variceal ligation: gold standard to control variceal bleeding after EVL: secondary prophylaxis (indefinitely until decompensated)
49
Octreotide
MOA: inhibits release of vasodilatory peptides (i.e. glucagon) resulting in splanchnic vasoconstriction and decrease in blood flow indications: acute variceal bleed (NOT otehr types of GI bleeding) - decreases mortality and transfusion in variceal bleeds SEs: N/V, HTN, bradycardia, hypergylcemia monitoring: s/sx, BP, HR, BG
50
EVL summary
gold standard for variceal bleeding cessation goal is EVL within 12 hrs upon presentation bands could break and/or new varices could form so not long-term solution
51
Primary antibiotic prophylaxis
indications: increased risk of infections with active variceal bleeding antibiotics recommended: 3rd gen cephalosporin (ceftriaxone) SE: diarrhea monitoring: s/sx of infection, not renally cleared so do NOT need to monitor SCr duration: until hemorrhage resolution (max 7 days) decrease mortality when used
52
Therapies NOT recommended
vitamin K although INR may be elevated, vit K is NOT recommended - data does not support improvement
53
Secondary prohylaxis for varices
EVL: every 1-4 weeks NSBBs: continue indefinitely (until decompensated) SE: drowsiness or insomnia, bradycardia, hypotensino monitoring: HR: goal 55-60 bpm, BP: SBP > 90 mmHg, s/sx of bleeding
54
EV summary
evaluate for primary prophylaxis to prevent variceal bleeding for variceal bleeding, acutely manage with transfusions, octreotide, antibiotic primary prophylaxis, and EVL after a variceal bleed, initiate secondary prophylaxis with NSBBs and/or EVL
55
What is the proposed underlying pathophysiology of HE?
hyperammonia
56
What are the primary s/sx of HE?
delirium, irritable temper, asterixis (inability to keep oustretched arms + hands in place)
57
What are objective markers that can be used to assess for HE?
EEG pattern: dyssynchronization of fast activity, slower delta activity, increased dysrhythmicity
58
For acute management, what are recommended therapies? (for HE)
lactulose 25 mL twice daily as 1st line agent rifaximin 550mg BID for recurrent HE 2nd line: large portosystemic shunts
59
Counseling points for a pt taking lactulose
goal of 3-5 bowel movements a day
60
Spontaneous bacterial peritonitis (SBP)
annual risk of SBP in pts with cirrhosis and ascites is 10-30% due to be from bacterial translocation, in which bacteria cross the intestinal barrier
61
SBP clinical presentation
fever, abdominal pain/tenderness, leukocytosis (increased WBC), encephalopathy, asymptomatic
62
SBP diagnosis
therapeutic paracentesis: positive ascitic fluid bacterial culture; ascitic fluid with >/= 250 cells/mm^3 polymorphonuclear leukocytes PMNs = WBC from fluid x % neutrophils
63
SBP treatment
antibiotics recommended: 3rd gen cephalosporin (ceftriaxone) SE: diarrhea monitoring: s/sx of infection (temp, WBC, cultures), not renally cleared so do NOT need to monitor SCr duration: 5-7 days
64
SBP treatment
albumin has been shown to decrease mortality and AKI/HRS in pts with SBP day 1: 1.5g/kg x1 day 3: 1g/kg x1 based on actual body weight!
65
SBP secondary prophylaxis
recurrence of SBP within 1 year is 70% recommended to initiate SBP secondary prophylaxis with antibiotics and avoid PPIs (which increase risk of SBP) sulfamethoxazole/trimethoprim (monitor: SCr, electrolytes, CBC), ciprofloxacin (monitor: mental status, CBC, renal fx) duration: indefinite
66
SBP summary
evaluate need for antibiotics for treatment: longer SBP treatment duration is not better initiate secondary SBP prophylaxis with bactrim or cipro monitor for SEs and future SBP
67
Other hepatic issues
drug dosing considerations in liver insufficiency viral hepatitis (C)
68
Dosing in liver insufficiency
no endogenous marker for heaptic clearance that can be used to guide drug dosing things to consider: extent of hepatic metabolism/activation of the med - decreased metabolism and activation with cirrhosis; severity of liver disease; highly protein bound drugs --> increase free drug conc, but not total drug conc; consider avoiding/limiting hepatotoxic meds
69
Hepatology management overview
evaulate risk factors, subjective/objective markers of acute and/or chronic liver insufficiency managment of acute liver injury is focused on removal/reversal of offending agent treating cirrhosis focuses on managing individual complications as they arise drug dosing in hepatic insufficiency is difficult

PHRM 864 Module 4 (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions